Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Leuprorelin acetate + Sintilimab
The First People's Hospital of Lianyungang
NSCLC, Stage III
1 trial -
Levofloxacin
The First People's Hospital of Lianyungang
Acute Ischemic Stroke
3 trials -
Lidocaine
The First People's Hospital of Lianyungang
Heart Failure
1 trial -
Lidocaine Hydrochloride 2% Injection Solution
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Colorectal Cancer
1 trial -
Lidocaine Hydrochloride, Injectable
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Primary Liver Cancer
1 trial -
Linaclotide
Second Affiliated Hospital of Xi'an Jiaotong University
Bowel Preparation
1 trial -
Linked Color Imaging
Hospital Authority, Hong Kong
Early Gastric Cancer
1 trial -
Liquid Biopsy (SPOT-MAS Assay)
Hospital Authority, Hong Kong
Lung Cancer
1 trial -
Liquid Biopsy Early Screening
The First People's Hospital of Lianyungang
Liquid Biopsy for Early Screening of Lung Cancer
1 trial -
Liraglutide
The First People's Hospital of Lianyungang
Ischemic Stroke
1 trial -
LiveSpo Navax
Hospital Authority, Hong Kong
Acute Respiratory Tract Infections
1 trial -
Losartan
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Healthy
1 trial -
Low dose midazolam
Hospital Authority, Hong Kong
Intubation
1 trial -
Low potassium content vegetables
Xiyuan Hospital of China Academy of Chinese Medical Sciences
End-stage Renal Disease
1 trial -
Lugol's Solution (1.5%)
Hospital Authority, Hong Kong
Esophageal Squamous Cell Neoplasm
1 trial -
Luo-Fu-Shan Plaster
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Arthritis, Rheumatoid
1 trial -
Luspatercept
The First People's Hospital of Lianyungang
Transfusion-dependent Non-severe Aplastic Anemia
1 trial -
Luvometinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Langerhans Cell Histiocytosis (LCH)
1 trial -
MR/PET
Hospital Authority, Hong Kong
Non-small Cell Lung Cancer
1 trial -
MTBF regimen
The First People's Hospital of Lianyungang
Relapse Leukemia
1 trial -
Magnesium Sulfate
Hospital Authority, Hong Kong
Myoma
1 trial -
Medical Management
The First People's Hospital of Lianyungang
Acute Ischemic Stroke
1 trial -
Medical Treatment
The First People's Hospital of Lianyungang
Basilar Artery Occlusion
1 trial -
Medical Treatment
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Carotid Artery Stenting
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources